» Articles » PMID: 33532992

Role of Traditional CHO PET Parameters in Distinguishing IDH, TERT and MGMT Alterations in Primary Diffuse Gliomas

Overview
Journal Ann Nucl Med
Date 2021 Feb 3
PMID 33532992
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Isocitrate dehydrogenase (IDH) mutation, telomerase reverse transcriptase (TERT) promoter mutation and O-methylguanine-DNA methyltransferase (MGMT) promoter methylation status are diagnostic, prognostic, predictive and therapeutic biomarkers for primary diffuse gliomas, and this study aimed to explore the relationship between choline (CHO) positron emission tomography (PET) parameters and these molecular alterations.

Methods: Twenty-eight patients who were histopathologically diagnosed with primary diffuse glioma and underwent presurgical CHO PET/CT were retrospectively analyzed, and IDH, TERT and MGMT alterations were examined. The volume of interest (VOI) was semiautomatically defined based on standardized uptake value (SUV) thresholds, and 5 traditional CHO parameters, namely, SUVmax, SUVmean, metabolic tumor volume (MTV), total lesion CHO uptake (TLC) and tumor-to-normal contralateral cortex activity ratio (T/N ratio), were calculated. Wilcoxon rank-sum tests and receiver operating characteristic (ROC) curves were applied to evaluate the differences and performances of the CHO parameters, and their capability to stratify patient prognosis was also evaluated.

Results: All 5 parameters were significantly higher in IDH-wildtype gliomas than in IDH-mutant gliomas (p = 0.0001-0.037), and SUVmax, SUVmean, TLC and the T/N ratio exhibited good performances in distinguishing the IDH status (areas under the ROC curve (AUCs) 0.856-0.918, accuracies 0.857-0.893) as well as stratifying patient prognosis. Although the differences and performances of the traditional parameters in distinguishing diverse TERT and MGMT statuses were moderate in the whole population, the T/N ratio and TLC displayed certain predictive value in discriminating the TERT status in the IDH-mutant and IDH-wildtype subgroups (p = 0.028-0.048, AUCs 0.857-0.860, accuracies 0.800-0.917, respectively).

Conclusions: Traditional CHO PET parameters are capable of distinguishing IDH but not TERT or MGMT alterations in the whole population. In accordance with the clinical understanding of TERT promoter mutations, the T/N ratio and TLC can also discriminate the TERT status in IDH subgroups.

Citing Articles

A histogram of [F]BBPA PET imaging differentiates non-neoplastic lesions from malignant brain tumors.

Kong Z, Li Z, Chen J, Shi Y, Li N, Ma W EJNMMI Res. 2024; 14(1):12.

PMID: 38305994 PMC: 10837405. DOI: 10.1186/s13550-024-01069-7.


A bis-boron boramino acid PET tracer for brain tumor diagnosis.

Li Z, Chen J, Kong Z, Shi Y, Xu M, Mu B Eur J Nucl Med Mol Imaging. 2024; 51(6):1703-1712.

PMID: 38191817 DOI: 10.1007/s00259-024-06600-5.


CT-based quantification of trachea shape to detect invasion by thyroid cancer.

Kong Z, Wang J, Ni S, Liu Y, Zhao X, Zhu Y Eur Radiol. 2023; 34(5):3141-3150.

PMID: 37926738 DOI: 10.1007/s00330-023-10301-2.


Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas.

Wu Y, Wang X, Zhang M, Wu D Molecules. 2023; 28(15).

PMID: 37570630 PMC: 10419986. DOI: 10.3390/molecules28155660.


Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas.

Neumaier F, Zlatopolskiy B, Neumaier B Molecules. 2023; 28(7).

PMID: 37049661 PMC: 10096429. DOI: 10.3390/molecules28072890.


References
1.
LaPointe S, Perry A, Butowski N . Primary brain tumours in adults. Lancet. 2018; 392(10145):432-446. DOI: 10.1016/S0140-6736(18)30990-5. View

2.
Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

3.
Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F . Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016; 18(11):1529-1537. PMC: 5063521. DOI: 10.1093/neuonc/now133. View

4.
Buckner J, Shaw E, Pugh S, Chakravarti A, Gilbert M, Barger G . Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016; 374(14):1344-55. PMC: 5170873. DOI: 10.1056/NEJMoa1500925. View

5.
Waitkus M, Diplas B, Yan H . Isocitrate dehydrogenase mutations in gliomas. Neuro Oncol. 2015; 18(1):16-26. PMC: 4677412. DOI: 10.1093/neuonc/nov136. View